Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
11 Jun 2024
Historique:
accepted: 29 05 2024
received: 22 08 2023
revised: 24 05 2024
medline: 11 6 2024
pubmed: 11 6 2024
entrez: 11 6 2024
Statut: aheadofprint

Résumé

Burkitt lymphoma (BL) is characterized by tumor microenvironment (TME) in which macrophages represent the main component, determining a distinct histological appearance known as "starry sky" pattern. However, in some instances, BL may exhibit a granulomatous reaction that has been previously linked to a favorable prognosis and spontaneous regression. The aim of our study was to deeply characterize the immune landscape of 7 cases of EBV + BL with granulomatous reaction compared to 8 cases of EBV + BL and 8 EBV- BL, both with typical "starry sky" pattern, by Gene expression profiling performed on the NanoString nCounter platform. Subsequently, the data were validated by multiplex and combined immunostaining. Based on unsupervised clustering of differentially expressed genes, BL samples formed 3 distinct clusters differentially enriched in BL with a diffuse granulomatous reaction (cluster 1), EBV+ BL with typical starry sky pattern (Cluster 2), EBV - BL with typical "starry sky" (cluster 3). We observed variations in the immune response signature among BL with granulomatous reaction and BL with typical "starry sky", both EBV + and EBV -. The TME signature in BL with diffuse granulomatous reaction showed a proinflammatory response, while BLs with "starry sky" were characterized by up-regulation of M2- polarization and pro-tumor response. Moreover, the analysis of additional signatures revealed an up-regulation of Dark zone-signature and epigenetic-signature in BL with typical "starry sky". Tumor associated macrophages (TAM) and epigenetic regulators may be promising targets for additional therapies in BL lymphoma opening novel immunotherapeutic strategies.

Identifiants

pubmed: 38861355
pii: 516459
doi: 10.1182/bloodadvances.2023011506
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Maria Chiara Siciliano (MC)

University of Siena, Siena, Italy.

Giorgio Bertolazzi (G)

University of Palermo, Department of Economics, Business, and Statistics, Italy.

Gaia Morello (G)

University of Palermo, palermo, Italy.

Salvatore Tornambè (S)

University of Siena, Siena, Italy.

Marcello Del Corvo (M)

European Institute of Oncology, IRCCS, Milan, Italy.

Massimo Granai (M)

University of Siena, Siena, Italy.

Maria Rosaria Sapienza (MR)

IEO European Institute of Oncology, Milan, Italy.

Ciara I Leahy (CI)

University of Limerick, Limerick, Ireland.

Eanna Fennell (E)

University of Limerick, Limerick, Ireland.

Beatrice Belmonte (B)

University of Palermo, Palermo, Italy.

Felice Arcuri (F)

University of Siena, siena, Italy.

Margherita Vannucchi (M)

University of Siena, siena, Italy.

Virginia Mancini (V)

Department of Medical Biotechnology, Siena, Italy.

Raffaella Guazzo (R)

University of Siena, Siena, Italy.

Roberto Boccacci (R)

University of Siena, Siena, Italy.

Noel Onyango (N)

University of Nairobi, Nairobi, Kenya.

Joshua Nyagol (J)

Univeristy of Nairobi, Nairobi, Kenya.

Raffaella Santi (R)

University of Florence, Florence, Italy.

Gioia Di Stefano (G)

Careggi Teaching Hospital, Florence, Tennessee, Italy.

Domenico Ferrara (D)

University of Siena, 53100, Italy.

Cristiana Bellan (C)

University of Siena, siena, Italy.

Teresa Marafioti (T)

University College London, London, United Kingdom.

German Ott (G)

Robert-Bosch-Krankenhaus, Stuttgart, Germany.

Reiner Siebert (R)

University of Ulm, Ulm, Germany.

Leticia Quintanilla-Fend (L)

University of Tuebingen, Tuebingen, Germany.

Falko Fend (F)

University Hospital and Comprehensive Cancer Center Tuebingen, Tuebingen, Germany.

Paul G Murray (PG)

University of Limerick, Limerick, Ireland.

Claudio Tripodo (C)

The FIRC Institute of Molecular Oncology, Italy.

Stefano Aldo Pileri (SA)

European Institute of Oncology IRCCS, Milan, Milan, Italy.

Stefano Lazzi (S)

University of Siena, Siena, Italy.

Lorenzo Leoncini (L)

University of siena, siena, Italy.

Classifications MeSH